<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc E De Broe, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gary C Curhan, MD, ScD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 31, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to kidney function impairment, prolonged heavy analgesic use can lead to two other major complications: urinary tract malignancy and atherosclerotic disease. The development of these conditions in patients with chronic analgesic abuse and analgesic nephropathy is discussed here. The effects of nonsteroidal antiinflammatory drugs (NSAIDs) on cardiovascular risk and the association between analgesics and the risk for hypertension are presented separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7968.html" rel="external">
          "NSAIDs: Adverse cardiovascular effects"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2385.html" rel="external">
          "NSAIDs and acetaminophen: Effects on blood pressure and hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          URINARY TRACT MALIGNANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transitional cell carcinomas of the kidney pelvis, ureter, and bladder (which may be multiple and bilateral) all occur with increased frequency in this setting [
         <a href="#rid1">
          1-3
         </a>
         ]. The incidence of renal cell carcinoma also may be enhanced, but this remains controversial [
         <a href="#rid4">
          4
         </a>
         ]. A large meta-analysis of 20 observational studies (14 with
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , 13 with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , and 5 with other nonsteroidal antiinflammatory drugs [NSAIDs]) found that acetaminophen and nonaspirin NSAIDs were associated with a significantly increased risk of developing kidney cancer (relative risk 1.28, 95% CI 1.15-1.44 and 1.25, 95% CI 1.06-1.46, respectively) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         It is estimated that a urinary tract malignancy will develop in as many as 8 to 10 percent of patients with analgesic nephropathy [
         <a href="#rid1">
          1-3
         </a>
         ] but in well under 1 percent of phenacetin-containing analgesic users without kidney disease [
         <a href="#rid6">
          6
         </a>
         ]. In women under the age of 50 years, for example, analgesic abuse is the most common cause of bladder cancer, an otherwise unusual disorder in young women [
         <a href="#rid3">
          3
         </a>
         ]. The potential magnitude of this problem has also been illustrated by histologic examination of nephrectomy specimens obtained prior to kidney transplantation; the incidence of urothelial atypia in this setting approaches 50 percent [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The tumors generally become apparent after 15 to 25 years of analgesic abuse [
         <a href="#rid1">
          1
         </a>
         ], usually, but not always, in patients with clinically evident analgesic nephropathy [
         <a href="#rid2">
          2
         </a>
         ]. There is no relationship between the degree of kidney failure in patients with analgesic nephropathy and the appearance of transitional cell carcinoma. Most patients are still taking the drug at the time of diagnosis, but clinically evident disease can first become apparent several years after cessation of analgesic intake and even after kidney transplantation has been performed [
         <a href="#rid1">
          1
         </a>
         ]. In Australia, for example, the incidence of analgesic nephropathy declined progressively in the first 10 years after phenacetin-containing compounds were removed from over-the-counter analgesic combinations and five years after over-the-counter sales of analgesic mixtures were banned [
         <a href="#rid7">
          7
         </a>
         ]. In comparison, the incidence of urinary tract malignancy continued to rise (at a greater rate than other malignancies), a possible reflection of late phenacetin-induced injury [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         It is presumed that the induction of malignancy results from the intrarenal accumulation of N-hydroxylated phenacetin metabolites that have potent alkylating action [
         <a href="#rid2">
          2
         </a>
         ]. Because of the urinary concentrating capacity of the kidney, the highest concentration of these metabolites will be in the renal medulla, ureters, and bladder, possibly explaining the predisposition to carcinogenesis at these sites.
        </p>
        <p>
         The pathogenetic importance of phenacetin metabolites is suggested indirectly from the observation that there appears to be no association with transitional cell carcinomas of the urinary tract with the prolonged ingestion of other analgesics that can cause papillary necrosis but do not form these metabolites, such as
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         and NSAIDs [
         <a href="#rid8">
          8-11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7176.html" rel="external">
          "Epidemiology and pathogenesis of analgesic-related chronic kidney disease"
         </a>
         .)
        </p>
        <p>
         The major presenting symptom of urinary tract malignancy in analgesic nephropathy is microscopic or gross hematuria. Thus, continued monitoring is essential, and new hematuria should be evaluated with urinary cytology and, if indicated, cystoscopy followed by computed tomography (CT) scan and/or magnetic resonance imaging (MRI) [
         <a href="#rid12">
          12
         </a>
         ]. It may also be prudent to obtain yearly urine cytology for the first several years, if analgesics are discontinued, or indefinitely, if drug intake persists. (See
         <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">
          "Etiology and evaluation of hematuria in adults"
         </a>
         .)
        </p>
        <p>
         The incidence of urothelial carcinoma after kidney transplantation in patients with analgesic nephropathy is comparable with the general incidence of up to 10 percent of urothelial carcinomas in end-stage kidney disease patients with analgesic nephropathy. Removal of the native kidneys prior to kidney transplantation has also been suggested, but the efficacy of this regimen has not been proven [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2989.html" rel="external">
          "Clinical presentation, diagnosis, and staging of bladder cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          ATHEROSCLEROSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with analgesic nephropathy are more likely to develop premature aging and graying and atherosclerotic vascular disease (including myocardial infarction and thrombotic stroke) [
         <a href="#rid6">
          6,13
         </a>
         ]. As examples, chronic ingestion of phenacetin-containing analgesic mixtures in women aged 30 to 49 years is, after 20 years, associated with a twofold increase in risk of myocardial infarction and a threefold increase in risk of all cardiovascular diseases [
         <a href="#rid6">
          6
         </a>
         ]. It is possible that the analgesic microangiopathy that is the earliest sign of kidney injury [
         <a href="#rid14">
          14
         </a>
         ] may play an important role in this problem; the incidence of other risk factors (such as hypercholesterolemia, smoking, and hypertension) does not appear to be enhanced when compared with patients with other forms of chronic kidney disease (CKD).
        </p>
        <p>
         The effects of nonsteroidal antiinflammatory drugs (NSAIDs) on cardiovascular risk and the association between analgesics and risk for hypertension are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7968.html" rel="external">
          "NSAIDs: Adverse cardiovascular effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2385.html" rel="external">
          "NSAIDs and acetaminophen: Effects on blood pressure and hypertension"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16275750">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urinary tract malignancy
         </strong>
         – Transitional cell carcinomas of the kidney pelvis, ureter, and bladder (which may be multiple and bilateral) all occur with increased frequency in patients with heavy analgesic use and analgesic nephropathy. There is no relationship between the degree of kidney failure in patients with analgesic nephropathy and the appearance of transitional cell carcinoma. (See
         <a class="local">
          'Urinary tract malignancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atherosclerosis
         </strong>
         – Patients with analgesic nephropathy, as is the case in other forms of chronic kidney failure, are more likely than those in the general population to develop premature atherosclerotic cardiovascular disease (including myocardial infarction and thrombotic stroke). (See
         <a class="local">
          'Atherosclerosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Blohmé I, Johansson S. Renal pelvic neoplasms and atypical urothelium in patients with end-stage analgesic nephropathy. Kidney Int 1981; 20:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCredie M, Stewart JH, Carter JJ, et al. Phenacetin and papillary necrosis: independent risk factors for renal pelvic cancer. Kidney Int 1986; 30:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 1985; 313:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow WH, McLaughlin JK, Linet MS, et al. Use of analgesics and risk of renal cell cancer. Int J Cancer 1994; 59:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choueiri TK, Je Y, Cho E. Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies. Int J Cancer 2014; 134:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubach UC, Rosner B, Stürmer T. An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987). N Engl J Med 1991; 324:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCredie M, Stewart JH, Mathew TH, et al. The effect of withdrawal of phenacetin-containing analgesics on the incidence of kidney and urothelial cancer and renal failure. Clin Nephrol 1989; 31:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCredie M, Stewart JH. Does paracetamol cause urothelial cancer or renal papillary necrosis? Nephron 1988; 49:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nanra RS. Analgesic nephropathy in the 1990s--an Australian perspective. Kidney Int Suppl 1993; 42:S86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen OM, Knudsen JB, Tomasson H, Sørensen BL. The Copenhagen case-control study of renal pelvis and ureter cancer: role of analgesics. Int J Cancer 1989; 44:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castelao JE, Yuan JM, Gago-Dominguez M, et al. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82:1364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang LJ, Lee SY, Teh BT, et al. Upper tract urothelial carcinomas in patients with chronic kidney disease: relationship with diagnostic challenge. Biomed Res Int 2014; 2014:989458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nanra RS, Stuart-Taylor J, de Leon AH, White KH. Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia. Kidney Int 1978; 13:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mihatsch MJ, Hofer HO, Gudat F, et al. Capillary sclerosis of the urinary tract and analgesic nephropathy. Clin Nephrol 1983; 20:285.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7177 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7045494" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Renal pelvic neoplasms and atypical urothelium in patients with end-stage analgesic nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3747346" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Phenacetin and papillary necrosis: independent risk factors for renal pelvic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4010740" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Heavy phenacetin use and bladder cancer in women aged 20 to 49 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7960214" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Use of analgesics and risk of renal cell cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23400756" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1984193" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2783667" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The effect of withdrawal of phenacetin-containing analgesics on the incidence of kidney and urothelial cancer and renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3412544" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Does paracetamol cause urothelial cancer or renal papillary necrosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8361137" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Analgesic nephropathy in the 1990s--an Australian perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2606581" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The Copenhagen case-control study of renal pelvis and ureter cancer: role of analgesics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10755416" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Non-steroidal anti-inflammatory drugs and bladder cancer prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25177705" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Upper tract urothelial carcinomas in patients with chronic kidney disease: relationship with diagnostic challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/362034" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6641031" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Capillary sclerosis of the urinary tract and analgesic nephropathy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
